Click here to get the latest information on the coronavirus (COVID-19) from Texas HHS.

BUPRENORPHINE-NALOX 4-1MG FILM

Drug Details

General

Brand Name: BUPRENORPHINE-NALOX 4-1MG FILM
Generic Name: buprenorphine HCl/naloxone HCl
Manufacturer: DR.REDDY'S LAB
NDC: 43598058030
Package size: 30EA
Family Planning drug: No
Diabetic Supply Drug: No
HTW drug: No
HTWPlus drug: No
Long-acting reversible contraception product: No
Refill-to-soon Utilization*: 90%

Drug Pricing

Retail Pharmacy Cost: 4.79044
Retail Pharmacy Eff Date: 03/23/2021
Specialty Pharmacy Cost: 4.7066
Specialty Pharmacy Eff Date: 03/23/2021
Long-term Care Pharmacy Cost: 4.67546
Long-term Care Pharmacy Eff Date: 03/23/2021
340B Cost: 2.72333
Premium Preferred Generic Incentive†: Yes

* Impacts only claims paid by the Vendor Drug Program: traditional Medicaid, CSHCN, HTW, and KHC Programs.

† Refer to the Pricing and Reimbursement chapter of the Pharmacy Provider Procedure Manual for information about traditional Medicaid claim pricing and PPG pricing incentives.

‡ Refer to the Clinical Prior Authorization Assistance Chart (PDF) for the list of clinical prior authorization each MCO uses and how those authorizations relate to those used in traditional Medicaid. Refer to the MCO Resources page for links to each MCO’s clinical prior authorizations.

Program Coverage

Medicaid

Effective date: 05/28/2019
PDL PA Required: No
PDL Class: OPIATE DEPENDENCE TREATMENTS
FFS Clinical PA Required‡: Yes
Compound-only use: No

CHIP

Effective date: 05/28/2019
Compound-only use: No

CSHCN

Effective date: 05/28/2019
Compound-only use: No

‡ Please review the lists of DUR board-approved clinical prior authorizations that apply to traditional Medicaid and those that health plans may use. The Pharmacy Clinical Prior Authorization Assistance Chart (PDF) shows the prior authorization each health plan uses and how those authorizations relate to the authorizations used for traditional Medicaid claim processing. Refer to the MCO Resources for links to each health plan's active clinical prior authorizations.